Technical Analysis for OPK - OPKO Health Inc.

Grade Last Price % Change Price Change
F 0.87 -3.27% -0.03
OPK closed down 3.27 percent on Monday, March 18, 2024, on 79 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -3.27%
Gapped Up Strength -3.27%
Oversold Stochastic Weakness -3.27%
New 52 Week Closing Low Bearish -2.25%
Below Lower BB Weakness -2.25%
Down 3 Days in a Row Weakness -2.25%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 13 hours ago
Down 3% about 13 hours ago
Fell Below Lower Bollinger Band about 14 hours ago
Down 2 % about 14 hours ago
Down 1% about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

OPKO Health Inc. Description

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Cancer Infectious Diseases Autoimmune Disease Pharmaceutical Products Alzheimer's Disease Phosphates Chemotherapy Prostate Cancer Non Small Cell Lung Cancer Vitamins Clinical Trial Antibiotics Kidney Disease Medical Test Ophthalmic Pancreatic Cancer Small Cell Lung Cancer Dialysis Influenza Biomarkers Asthma Diagnostic Tests Molecular Diagnostics Chronic Obstructive Pulmonary Disease Hormones Pulmonary Disease Thyroid Active Pharmaceutical Ingredients Heart Disease Chronic Kidney Disease End Stage Renal Disease Hemodialysis Renal Disease Metabolic Disorders Oligonucleotide Stage Renal Disease Pathology Influenza Vaccine Medical Laboratory Nausea Organ Failure Vascular Products Cardiovascular Products Heparin Chemotherapy Induced Nausea Hyperparathyroidism Hyperphosphatemia OLAP Opko Health Secondary Hyperparathyroidism

Is OPK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.24
52 Week Low 0.8516
Average Volume 13,559,570
200-Day Moving Average 1.46
50-Day Moving Average 0.98
20-Day Moving Average 0.96
10-Day Moving Average 0.92
Average True Range 0.05
RSI (14) 32.89
ADX 20.36
+DI 12.59
-DI 27.49
Chandelier Exit (Long, 3 ATRs) 0.92
Chandelier Exit (Short, 3 ATRs) 1.01
Upper Bollinger Bands 1.05
Lower Bollinger Band 0.87
Percent B (%b) 0.0
BandWidth 19.73
MACD Line -0.04
MACD Signal Line -0.03
MACD Histogram -0.006
Fundamentals Value
Market Cap 603.25 Million
Num Shares 697 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -3.09
Price-to-Sales 0.84
Price-to-Book 0.50
PEG Ratio -2.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.93
Resistance 3 (R3) 0.94 0.92 0.92
Resistance 2 (R2) 0.92 0.91 0.92 0.92
Resistance 1 (R1) 0.89 0.90 0.89 0.89 0.92
Pivot Point 0.88 0.88 0.87 0.87 0.88
Support 1 (S1) 0.85 0.86 0.84 0.84 0.82
Support 2 (S2) 0.83 0.85 0.83 0.81
Support 3 (S3) 0.80 0.83 0.81
Support 4 (S4) 0.80